CMV poses particular concerns for cancer patients, who often have weakened immune systems due to their illness and treatments like chemotherapy. The reactivation of CMV in these patients can lead to additional complications, including increased risk of infections and altered drug metabolism. Understanding the interplay between CMV and cancer therapies is vital for developing effective treatment plans and minimizing toxicological risks.
